CRIS Current Research Information System

DE GIOVANNI, CARLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.965
EU - Europa 2.442
AS - Asia 1.178
AF - Africa 233
SA - Sud America 13
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 7.844
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.930
GB - Regno Unito 682
CN - Cina 460
IT - Italia 431
DE - Germania 310
VN - Vietnam 285
SG - Singapore 270
SE - Svezia 252
UA - Ucraina 152
CH - Svizzera 127
IN - India 112
RU - Federazione Russa 112
IE - Irlanda 96
CI - Costa d'Avorio 93
FR - Francia 91
TG - Togo 56
ZA - Sudafrica 55
EE - Estonia 43
CA - Canada 34
BG - Bulgaria 33
BE - Belgio 30
FI - Finlandia 19
NL - Olanda 17
RO - Romania 15
SC - Seychelles 15
ID - Indonesia 13
JP - Giappone 12
NG - Nigeria 11
JO - Giordania 9
BR - Brasile 6
HR - Croazia 6
AU - Australia 5
GR - Grecia 5
IR - Iran 5
CL - Cile 4
DK - Danimarca 4
EU - Europa 4
ES - Italia 3
HK - Hong Kong 3
LT - Lituania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AR - Argentina 2
AT - Austria 2
EG - Egitto 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PL - Polonia 2
TR - Turchia 2
EC - Ecuador 1
IL - Israele 1
IQ - Iraq 1
KR - Corea 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MY - Malesia 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 7.844
Salva come PNG Salva come JPEG
Città #
Southend 580
Fairfield 523
Chandler 484
Ashburn 323
Houston 265
Woodbridge 242
Singapore 232
Wilmington 228
Ann Arbor 208
Seattle 200
Dong Ket 161
Cambridge 155
Princeton 148
Santa Clara 138
Bologna 116
Jacksonville 106
Bern 101
Dublin 96
Abidjan 93
Boardman 86
Westminster 59
Lomé 56
Nanjing 56
Padova 54
Berlin 39
Bremen 36
Beijing 35
Sofia 32
Jinan 31
Brussels 30
San Diego 30
Redwood City 29
Saint Petersburg 28
Shenyang 26
Guangzhou 24
Mülheim 23
Nanchang 22
Tianjin 22
Hebei 21
Redmond 19
Turin 19
Changsha 18
Helsinki 18
Des Moines 16
Falls Church 16
Milan 16
Bulle 15
Jiaxing 15
Mahé 15
Ottawa 15
Jakarta 13
Shanghai 13
London 12
New York 12
Zhengzhou 12
Tokyo 11
Abeokuta 10
Hangzhou 10
Phoenix 10
Toronto 10
Amman 9
Amsterdam 9
Los Angeles 9
Moscow 9
Taizhou 9
Verona 9
Casalecchio di Reno 8
Kuban 8
Falkenstein 7
Haikou 7
Medford 7
Shijiazhuang 7
Taiyuan 7
Bühl 6
Dearborn 6
Ningbo 6
Delhi 5
Lanzhou 5
Leawood 5
Norwalk 5
Reggio Nell'emilia 5
San Venanzo 5
São Paulo 5
Argelato 4
Chieti 4
Crotone 4
Kilburn 4
Lausanne 4
Olalla 4
Paris 4
Parma 4
Porto Recanati 4
Stockholm 4
Zanjan 4
Buffalo 3
Chengdu 3
Harbin 3
Hefei 3
Las Vegas 3
Muizenberg 3
Totale 5.653
Salva come PNG Salva come JPEG
Nome #
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 250
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 210
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 198
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 179
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 177
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 169
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 162
Rethinking herpes simplex virus: the way to oncolytic agents. 162
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 155
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 155
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 151
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 151
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 147
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 146
Oncolytic herpes virus retargeted to HER-2. 140
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 139
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 138
Antimetastatic activity of a preventive cancer vaccine. 136
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 136
Immunoprevention and immunotherapy of mammary carcinoma 134
Immunological prevention of a multigene cancer syndrome 132
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 131
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 131
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 130
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 130
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 129
Herpesviruses as oncolytic agents 128
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 128
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 125
In silico modeling and in vivo efficacy of cancer preventive vaccinations 124
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 121
2011: the immune hallmarks of cancer 120
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 120
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 120
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 119
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 118
Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous 117
New target antigens for cancer immunoprevention 116
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 116
A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. 116
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 115
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 113
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 113
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. 112
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 112
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 111
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 111
The molecular basis of herpesviruses as oncolytic agents. 111
Molecular and cellular biology of rhabdomyosarcoma 109
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 109
Delivery of CD44shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ mice. 104
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 103
Vaccines and other immunological approaches for cancer immunoprevention 101
Preclinical vaccines against mammary carcinoma. 100
null 98
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 97
Cancer biology, what we know and what we don't know. 96
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 96
Gene expression profiling differences between synchronous and metachronous metastases of colorectal cancer. 89
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 83
Methods of treating bone cancer 72
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 70
Immunotherapy 64
Cancer immunoprevention 54
Totale 8.049
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.261
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.261
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.175 0 0 0 0 0 0 255 284 257 157 117 105
2020/20211.125 223 63 42 56 19 54 34 112 126 56 36 304
2021/20221.384 144 40 105 57 124 85 42 101 52 97 310 227
2022/20231.656 203 237 91 226 105 111 43 81 203 72 136 148
2023/2024328 17 63 20 34 23 57 24 30 4 23 10 23
2024/2025866 135 179 130 72 228 97 25 0 0 0 0 0
Totale 8.049